Aeterna Zentaris Inc., of Charleston, S.C., said it priced a public offering of 26.66 million units at 45 cents each for gross proceeds of $12 million. Each unit contains one common share and one common warrant to purchase one common share. The company’s shares (NASDAQ:AEZS) closed July 2 at 38 cents, down 30%.

Annexon Inc., of South San Francisco, said it closed a $100 million financing led by new investor Redmile Group. The financing is intended to advance multiple product candidates in the company’s portfolio, including ANX-005, an investigational monoclonal antibody designed to block C1q and activation of the classical complement cascade, that is advancing into a phase II/III trial in patients with Guillain-Barré syndrome, with additional plans to advance into warm autoimmune hemolytic anemia, Huntington’s disease and amyotrophic lateral sclerosis. It will also support ANX-007, an investigational C1q antigen-binding fragment, or Fab, designed for intravitreal administration in patients with complement-mediated neurodegenerative ophthalmic disorders, that is advancing into a phase II trial in geographic atrophy.

CF Pharmtech Inc., of Suzhou, China, said it raised $50 million in series F financing following its $90 million series E financing in January. The company is developing a pipeline of more than 20 products for China and global markets that fall into four categories, namely metered dose inhalers, nasal sprays, nebulized and dry powder inhalers.

Derm-Biome Pharmaceuticals Inc., of Vancouver, British Columbia, said it has raised $500,000 in pre-seed funding, which will allow it to advance its anti-aging (skin rejuvenation) and atopic dermatitis topicals to the clinic by the first quarter of 2021. It also has spun out biotech firm Pan-Biome Pharmaceuticals Inc., which will focus on developing treatments for chronic inflammatory disease, starting with early stage small molecules that have shown anti-inflammatory activity in preclinical testing. The compounds also have antimicrobial activity to potentially help balance and diversify the gut microbiome, the company said.

Mimedx Group Inc., of Marietta, Ga., said it closed concurrent private equity and debt financings totaling $150 million, consisting of an equity financing relating to a securities purchase agreement with an entity controlled by EW Healthcare Partners and certain funds managed by Hayfin Capital Management LLP and a debt financing related to a loan agreement with Hayfin. The aggregate proceeds have been or will be used to repay the outstanding principal, interest and prepayment premium resulting from the early termination of the company’s term loan agreement with Blue Torch Finance LLC and for working capital and general corporate purposes.

Neoleukin Therapeutics Inc., of Seattle, said it intends to offer and sell, subject to market and other conditions, up to 5 million shares and, in lieu of common stock, to offer and sell to certain investors prefunded warrants to purchase shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares. The net proceeds from the offering, together with existing cash resources, will be used to advance development of a lead program, NL-201, to expand its de novo protein design technology, to develop its preclinical pipeline and to fund working capital and for general corporate purposes. The company’s shares (NASDAQ:NLTX) closed Thursday at $14, down 17.7%.

No Comments